Acelyrin (SLRN) Expected to Announce Earnings on Thursday

Acelyrin (NASDAQ:SLRN) will likely be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

Acelyrin (NASDAQ:SLRN) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.07. On average, analysts expect Acelyrin to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acelyrin Stock Performance

Acelyrin stock opened at $2.51 on Wednesday. The stock’s 50 day moving average price is $2.31 and its two-hundred day moving average price is $3.78. The stock has a market capitalization of $252.78 million, a price-to-earnings ratio of -1.02 and a beta of 1.27. Acelyrin has a 52-week low of $1.85 and a 52-week high of $7.25.

Insider Transactions at Acelyrin

In other news, CEO Mina Kim sold 17,986 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $2.74, for a total value of $49,281.64. Following the completion of the sale, the chief executive officer now owns 671,753 shares in the company, valued at $1,840,603.22. This represents a 2.61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 13.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on SLRN shares. Citigroup reduced their price target on shares of Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. HC Wainwright decreased their target price on Acelyrin from $8.00 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday, January 7th. Finally, Wells Fargo & Company cut their price target on Acelyrin from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $9.60.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.